US President Donald Trump ’s move to impose 100% tariffs on branded and patented pharmaceutical exports has rattled Indian pharma stocks, even though most companies earn from US markets by selling generic drugs. For Indian pharmaceutical exports, the US represents the primary market, comprising approximately 35% of total exports, with a value reaching about $10 billion in FY25. This development caused a negative impact on stock prices, with major pharmaceutical companies like Sun Pharma , Cipla, and Dr. Reddy's seeing declines of up to 5%. Experts are evaluating potential impact on companies deriving 30-47% of their revenue from US operations, particularly if Trump's tariff policy expands to include complex generics and specialty medicines. "President Trump's tantrums with tari

See Full Page